GLP-1 medications like Ozempic and Wegovy are reshaping diabetes and weight-loss care, but new studies raise questions about bone health in older adults, suggesting clinicians should balance metabolic benefits with fracture risk and plan screening and prevention up front.
Recent research looked at people 65 and older with type 2 diabetes who began GLP-1 therapy and found an 11% higher risk of fragility fractures compared with peers on other diabetes drugs. The study followed more than 46,000 older adults for nearly three years and after statistical adjustments the increased fracture risk was modest but statistically significant. That kind of relative increase matters when you are dealing with a group already vulnerable to falls and bone loss.
Lead investigators emphasized caution. “Both older age and type 2 diabetes are independent risk factors for fragility fractures,” Kasher Meron said, calling attention to a population that needs extra vigilance. The research was observational, so it reveals an association rather than a direct cause-and-effect link, leaving open several possible explanations for the finding.
Another analysis presented at a major orthopedic meeting broadened the concern, reporting a 29% higher relative risk of osteoporosis among GLP-1 users with obesity and diabetes across five years. That study also noted slightly higher rates of gout and a rare increase in osteomalacia among users, though it too was observational and not yet peer-reviewed. Observational signals can guide caution but they are not definitive proof.
Several plausible mechanisms could explain why bone strength appears affected when people lose weight rapidly on potent GLP-1 drugs. Significant weight loss reduces the mechanical load bones carry, and less load often means declining bone density over time. “There’s nothing forcing their bones to kind of hold their weight anymore. And a lot of those astronauts come back with low bone density,” Dr. John Horneff said, using a space-flight analogy to illustrate how unloading leads to bone loss.
Beyond mechanical unloading, reduced calorie intake can lower the consumption of calcium, vitamin D and protein, all essential nutrients for maintaining bone and muscle. Rapid weight changes can also increase uric acid temporarily, which may explain a modest rise in gout cases among some users. Muscle loss during weight loss further undermines balance and raises the risk of falls that can lead to fractures.
Clinicians and patients should consider bone health proactively when starting GLP-1 therapy in older adults. Experts suggest baseline bone density screening for at-risk patients, attention to nutritional intake, and incorporating resistance training to preserve muscle and support skeletal strength. Small, deliberate steps—adequate protein, vitamin D, and weight-bearing exercise—can mitigate some of the potential downsides of rapid weight loss.
Pharmaceutical manufacturers have reiterated their commitment to safety and point to the documented benefits of GLP-1 medications for blood sugar control, weight reduction, and cardiovascular outcomes when used under medical supervision. “Osteoporosis is a complex condition that develops over many years as a result of interdependent risk factors,” Skrbkova said, stressing that bone disease rarely stems from a single cause and that safety profiles are reflected in current regulatory labeling.
Patients and clinicians must balance competing priorities: the clear metabolic advantages of GLP-1 therapy for many people with diabetes and obesity, and the emerging signals about bone health in older adults. That balance means monitoring, tailored lifestyle support, and sensible screening rather than abandoning effective therapies. Thoughtful care plans can preserve the gains in weight and glucose control while guarding bone strength and mobility.
As the field collects more long-term, controlled data, the message is practical: treat the whole patient. Assess fracture risk before starting therapy in older adults, support nutrition and resistance exercise, and remain alert to symptoms that could signal bone problems. Early prevention and sensible follow-up will help patients get benefits without paying an unnecessary price in bone health.
